ECSP24039278A - Unidades de unión multiespecíficas que comprenden los dominios de unión a pd-1 y tgf-brii - Google Patents

Unidades de unión multiespecíficas que comprenden los dominios de unión a pd-1 y tgf-brii

Info

Publication number
ECSP24039278A
ECSP24039278A ECSENADI202439278A ECDI202439278A ECSP24039278A EC SP24039278 A ECSP24039278 A EC SP24039278A EC SENADI202439278 A ECSENADI202439278 A EC SENADI202439278A EC DI202439278 A ECDI202439278 A EC DI202439278A EC SP24039278 A ECSP24039278 A EC SP24039278A
Authority
EC
Ecuador
Prior art keywords
tgf
binding
multispecific
brii
multispecific binding
Prior art date
Application number
ECSENADI202439278A
Other languages
English (en)
Spanish (es)
Inventor
Liang-Chuan Wang
Shaun M Stewart
Cecilia Anna Wilhelmina Geuijen
Patrick Mayes
Original Assignee
Incyte Corp
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp, Merus Nv filed Critical Incyte Corp
Publication of ECSP24039278A publication Critical patent/ECSP24039278A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ECSENADI202439278A 2021-11-19 2024-05-21 Unidades de unión multiespecíficas que comprenden los dominios de unión a pd-1 y tgf-brii ECSP24039278A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2029844 2021-11-19
PCT/EP2022/082377 WO2023089083A1 (en) 2021-11-19 2022-11-18 Multispecific binding moieties comprising pd-1 and tgf-brii binding domains

Publications (1)

Publication Number Publication Date
ECSP24039278A true ECSP24039278A (es) 2024-07-31

Family

ID=80625531

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202439278A ECSP24039278A (es) 2021-11-19 2024-05-21 Unidades de unión multiespecíficas que comprenden los dominios de unión a pd-1 y tgf-brii

Country Status (18)

Country Link
US (1) US20230159645A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433505A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542879A (cg-RX-API-DMAC7.html)
KR (1) KR20240101664A9 (cg-RX-API-DMAC7.html)
CN (2) CN119613560A (cg-RX-API-DMAC7.html)
AR (1) AR127714A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022389596A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231649A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001410A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024006325A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240201A (cg-RX-API-DMAC7.html)
EC (1) ECSP24039278A (cg-RX-API-DMAC7.html)
IL (1) IL312214A (cg-RX-API-DMAC7.html)
MX (1) MX2024006018A (cg-RX-API-DMAC7.html)
PE (1) PE20241477A1 (cg-RX-API-DMAC7.html)
TW (1) TW202328180A (cg-RX-API-DMAC7.html)
UY (1) UY40028A (cg-RX-API-DMAC7.html)
WO (1) WO2023089083A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121152809A (zh) * 2023-04-14 2025-12-16 因赛特公司 抗TGFβR2/PD-1双特异性抗体治疗癌症的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CN110198738A (zh) * 2017-01-07 2019-09-03 默克专利有限公司 用于靶向的TGF-β抑制的给药方案和剂型
TWI917306B (zh) * 2017-07-06 2026-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的結合分子
TWI887193B (zh) * 2017-07-06 2025-06-21 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
CN116199780A (zh) * 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业(上海)股份有限公司 四价双特异性抗体、其制备方法和用途
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii

Also Published As

Publication number Publication date
AU2022389596A1 (en) 2024-05-30
PE20241477A1 (es) 2024-07-17
CL2024001410A1 (es) 2024-08-30
MX2024006018A (es) 2024-07-29
CN119613560A (zh) 2025-03-14
AR127714A1 (es) 2024-02-21
JP2024542879A (ja) 2024-11-18
TW202328180A (zh) 2023-07-16
US20230159645A1 (en) 2023-05-25
CA3231649A1 (en) 2023-05-25
IL312214A (en) 2024-06-01
KR20240101664A9 (ko) 2025-12-10
CN118265725A (zh) 2024-06-28
EP4433505A1 (en) 2024-09-25
KR20240101664A (ko) 2024-07-02
CR20240201A (es) 2024-07-15
WO2023089083A1 (en) 2023-05-25
CO2024006325A2 (es) 2024-06-27
UY40028A (es) 2023-05-31

Similar Documents

Publication Publication Date Title
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
BR112018073328A2 (pt) combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
BR112013027307A2 (pt) método para tratar uma matriz de tecido; matriz de tecido acelular
MX2020004858A (es) Compuestos moduladores de sting y metodos de elaboracion y uso.
MX392459B (es) Composicion farmaceutica para la prevencion o tratamiento de cancer, que comprende polimorfo cristalino de hexoxido de tetraarsenico
MX2017013413A (es) Compuestos de pirazol y metodo para elaborar y usar los compuestos.
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
MX2019005246A (es) Aparato y metodo para generar una trama de se?ales de difusion usando multiplexacion de division en capas.
MX2024002391A (es) Inhibidores de indolina de kif18a.
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
NI201100056A (es) Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyética y su uso para tratar enfermedades mediadas por prostaglandina d2.
MX2021000154A (es) Metodos de tratamiento de fibrosis hepatica que usan inhibidores de calpaina.
MX2016009225A (es) Composiciones en forma de suspension modificadas para formar recubrimientos de cromo por difusion.
MX382564B (es) Aparato y metodo para generar una trama de señal de radiodifusion que incluye un preambulo para la señalizacion de informacion de nivel de inyeccion.
MX2021004709A (es) Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1.
CL2024001410A1 (es) Unidades de unión multiespecíficas que comprenden los dominios de unión a pd-1 y tgf-brii
BR112017028362A2 (pt) composições aditivas para a eliminação de sulfeto de hidrogênio, e o meio compreendendo as mesmas
CO2021007006A2 (es) Moduladores de la expresión de irf5
CO2024012454A2 (es) Composiciones que comprenden aticaprant
AR131685A1 (es) 1h-pirazol-4-carboxamidas sustituidas como inhibidores de sarm1
CO2021017740A2 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1